D.A. Davidson & CO. boosted its stake in Balchem Co. (NASDAQ:BCPC) by 18.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,852 shares of the basic materials company’s stock after purchasing an additional 601 shares during the period. D.A. Davidson & CO.’s holdings in Balchem were worth $302,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the stock. Bank of Montreal Can raised its stake in shares of Balchem by 13.6% during the fourth quarter. Bank of Montreal Can now owns 1,926 shares of the basic materials company’s stock valued at $151,000 after acquiring an additional 231 shares during the last quarter. Quantamental Technologies LLC bought a new position in shares of Balchem during the fourth quarter valued at $188,000. Hsbc Holdings PLC bought a new position in shares of Balchem during the third quarter valued at $212,000. Bbva Compass Bancshares Inc. bought a new position in shares of Balchem during the third quarter valued at $226,000. Finally, Citadel Advisors LLC bought a new position in shares of Balchem during the third quarter valued at $247,000. 91.12% of the stock is owned by institutional investors and hedge funds.
BCPC opened at $82.95 on Tuesday. Balchem Co. has a twelve month low of $70.98 and a twelve month high of $117.79. The company has a quick ratio of 2.33, a current ratio of 3.42 and a debt-to-equity ratio of 0.27. The firm has a market cap of $2.66 billion, a PE ratio of 32.79 and a beta of 0.91.
The company also recently disclosed an annual dividend, which was paid on Friday, January 18th. Stockholders of record on Wednesday, December 26th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Monday, December 24th. This is a boost from Balchem’s previous annual dividend of $0.42. This represents a dividend yield of 0.59%. Balchem’s dividend payout ratio is 18.58%.
Several research firms have recently issued reports on BCPC. HC Wainwright set a $101.00 price target on shares of Balchem and gave the company a “buy” rating in a research note on Monday, December 10th. Zacks Investment Research raised shares of Balchem from a “sell” rating to a “hold” rating in a research note on Monday. BidaskClub raised shares of Balchem from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 12th. ValuEngine downgraded shares of Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Finally, Sidoti raised shares of Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price target for the company in a research note on Tuesday, October 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $109.33.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Featured Story: Cost of Equity
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.